Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
|Articles|May 1, 2001
Supplements and Featured Publications
- Artherosclerosis: Achieving Optimal Outcomes in Statin Therapy
- Volume 7
- Issue 5 Suppl
Should All Patients with Cardiovascular Disease Receive Statin Therapy?
Author(s)Robert Vogel, MD, Ernst Schaefer, MD
Advertisement
Articles in this issue
over 25 years ago
Participating Facultyover 25 years ago
Introductionover 25 years ago
Threshold Level or Not for Low-Density Lipoprotein Cholesterolover 25 years ago
Statins--Differences and Similaritiesover 25 years ago
What Do the Statin Trials Tell Us?over 25 years ago
New Therapies on the Horizonover 25 years ago
A New Statin: A New StandardAdvertisement
Related to this article
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
NPC researchers examined questions about how these policies could affect patients, pharmacies, and providers.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
A historical review traces Sjögren disease from its early descriptions to the use of salivary gland ultrasound in diagnosis.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5